---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-041394"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:18:17.902708+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo/Pfizer Alta study: 4-year data shows mean ABR 1.4, sustained FVIII activity

## Summary
- Cohort 4 (3e13 vg/kg) mean ABR 1.4, median 0.0; 3 of 5 participants had zero bleeds post-infusion.
- FVIII activity maintained in mild-to-normal range in 4 of 5 participants over 4-year follow-up; 1 participant had FVIII BLOQ.
- No new safety signals; no thrombotic, neoplastic events, or FVIII inhibitors; LFT elevations resolved with steroids.
- Pfizer expects pivotal Phase 3 AFFINE readout mid-2024.

## SEC filing metadata
- accession: 0001628280-23-041394
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828023041394/0001628280-23-041394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828023041394/sgmo-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-041394
- JSON: https://secwatch.observer/filing/0001628280-23-041394.json
- Plain text: https://secwatch.observer/filing/0001628280-23-041394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.